Abstract
Plasma level of the protein VAP-1/SSAO (Vascular Adhesion Protein-1/ Semicarbazide-Sensitive Amine Oxidase) is increased in diabetes and/or obesity and may be related to vascular complications associated to these pathologies. The aim of this work was to complete a preceding study where we described the role played by some hormones or metabolites, implicated in diabetes and/or obesity, in the regulation of the release of VAP-1/SSAO by 3T3-L1 adipocytes. Here we focused on the previously observed effect produced by TNFα in the release of VAP-1/SSAO and studied the effect of a beta-adrenergic compound, isoproterenol. Both compounds stimulated the release of VAP-1/SSAO to the culture medium but had a different effect on the VAP-1/SSAO membrane form. Shile TNFα produced a decrease on VAP-1/SSAO membrane form content, isoproterenol did not modify it. We thus observed two different ways of regulation of the release of VAP-1/SSAO by 3T3-L1 adipocytes by metabolites implicated in diabetes and adipose tissue physiopathology. Our work permits a better understanding of this increased plasma VAP-1/SSAO levels observed in diabetes.
Resumen
Los niveles plasmáticos de proteína VAP-1/SSAO están aumentados en la diabetes y la obesidad, lo que podría estar relacionado con las complicaciones vasculares asociadas a estas patologías. En continuidad con trabajos anteriores acerca del papel de algunas hormonas o metabolitos, implicados en la diabetes y obesidad, se estudia en este trabajo el efecto producido por el TNFα y del agonista beta-adrenérgico isoproterenol en la regulación de la liberación de VAP-1/SSAO por adipocitos 3T3-L1. Ambos compuestos estimularon cultivo, pero tuvieron un efecto diferente sobre la isoforma ligada a la membrana de VAP-1/SSAO. Así, mientras que el TNFα produjo una disminución significativa en la actividad VAP-1/SSAO ligada a la membrana, no se modificó por el isoproterenol. Además, se observan dos maneras diferentes de regulación de la liberación de VAP-1/SSAO por adipocitos 3T3-L1 a través de metabolitos implicados en la diabetes by fisiopatología del tejido adiposo. Nuestro trabajo puede contribuir a elucidar los factores implicados en el aumento de los niveles plasmáticos de VAP-1/SSAO en la diabetes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abella, A., Garcia-Vicente, S., Viguerie, N., Ros-Baro, A., Camps, M., Palacin, M., Zorzano, A. and Marti, L. (2004):Diabetologia,47, 429–438.
Abella, A., Marti, L., Carpene, C., Palacin, M., Testar, X. and Zorzano, A. (2003):J. Physiol. Biochem.,59, 153–160.
Ahima, R. S. and Flier, J. S. (2000):Trends Endocrinol. Metab.,11, 327–332.
Blann, A. D., Tse, W., Maxwell, S. J. and Waite, M. A. (1994):J. Hypertens.,12, 925–928.
Bono, P., Jalkanen, S. and Salmi, M. (1999):Am. J. Pathol.,155, 1613–1624.
Boomsma, F., van den Meiracker, A. H., Winkel, S., Aanstoot, H. J., Batstra, M. R., Man in ’t Veld, A. J. and Bruining, G. J. (1999):Diabetologia,42, 233–237.
Boomsma, F., van Veldhuisen, D. J., de Kam, P. J., Man, i. V, Mosterd, A., Lie, K. I. and Schalekamp, M. A. (1997):Cardiovasc. Res.,33, 387–391.
Butcher, E. C. and Picker, L. J. (1996):Science,272, 60–66.
Enrique-Tarancon, G., Marti, L., Morin, N., Lizcano, J. M., Unzeta, M., Sevilla, L., Camps, M., Palacin, M., Testar, X., Carpene, C. and Zorzano, A. (1998):J. Biol. Chem.,273, 8025–8032.
Fowler, C. J. and Tipton, K. F. (1981):Biochem. Pharmacol.,30, 3329–3332.
Gearing, A. J. and Newman, W. (1993):Immunol. Today,14, 505–512.
Hackman, A., Abe, Y., Insull, W., Jr., Pownall, H., Smith, L., Dunn, K., Gotto, A. M., Jr. and Ballantyne, C. M. (1996):Circulation,93, 1334–1338.
Hayes, B. E. and Clarke, D. E. (1990):Res. Commun. Chem. Pathol. Pharmacol.,69, 71–83.
Kurkijarvi, R., Adams, D. H., Leino, R., Mottonen, T., Jalkanen, S. and Salmi, M. (1998):J. Immunol.,161, 1549–1557.
Kurkijarvi, R., Jalkanen, S., Isoniemi, H. and Salmi, M. (2001):Eur. J. Immunol.,31, 2876–2884.
Lampeter, E. R., Kishimoto, T. K., Rothlein, R., Mainolfi, E. A., Bertrams, J., Kolb, H. and Martin, S. (1992):Diabetes,41, 1668–1671.
Leinonen, E., Hurt-Camejo, E., Wiklund, O., Hulten, L. M., Hiukka, A. and Taskinen, M. R. (2003):Atherosclerosis,166, 387–394.
Meszaros, Z., Szombathy, T., Raimondi, L., Karadi, I., Romics, L. and Magyar, K. (1999):Metabolism,48, 113–117.
Moldes, M., Feve, B. and Pairault, J. (1999):J. Biol. Chem.,274, 9515–9523.
Morandini, R., Ghanem, G., Portier-Lemarie, A., Robaye, B., Renaud, A. and Boeynaems, J. M. (1996):Am. J. Physiol.,270, H807-H816.
Ridker, P. M., Hennekens, C. H., Roitman-Johnson, B., Stampfer, M. J. and Allen, J. (1998):Lancet,351, 88–92.
Ros-Baro, A., Lopez-Iglesias, C., Peiro, S., Bellido, D., Palacin, M., Zorzano, A. and Camps, M. (2001):Proc. Natl. Acad. Sci. USA,98, 12050–12055.
Salmi, M. and Jalkanen, S. (1992):Science,257, 1407–1409.
Salmi, M., Stolen, C., Jousilahti, P., Yegutkin, G. G., Tapanainen, P., Janatuinen, T., Knip, M., Jalkanen, S. and Salomaa, V. (2002):Am. J. Pathol.,161, 2255–2262.
Smith, D. J., Salmi, M., Bono, P., Hellman, J., Leu, T. and Jalkanen, S. (1998):J. Exp. Med.,188, 17–27.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
García-Vicente, S., Abella, A., Viguerie, N. et al. The release of soluble VAP-1/SSAO by 3T3-L1 adipocytes is stimulated by isoproterenol and low concentrations of TNFα. J. Physiol. Biochem. 61, 395–401 (2005). https://doi.org/10.1007/BF03167057
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03167057